Review



p hp1γ ser83  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc p hp1γ ser83
    (A) Representative images of <t>p-HP1γ.</t> Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.
    P Hp1γ Ser83, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+hp1%CE%B3+ser83/pmc07190998-519-48-49?v=Cell+Signaling+Technology+Inc
    Average 92 stars, based on 13 article reviews
    p hp1γ ser83 - by Bioz Stars, 2026-07
    92/100 stars

    Images

    1) Product Images from "CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo"

    Article Title: CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI131133

    (A) Representative images of p-HP1γ. Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.
    Figure Legend Snippet: (A) Representative images of p-HP1γ. Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.

    Techniques Used: Staining, Western Blot, Quantitative RT-PCR, Expressing, Transfection, Binding Assay, Negative Control



    Similar Products

    rabbit polyclonal anti-p-hp1γ (ser83)  (Thermo Fisher)
    90
    Thermo Fisher rabbit polyclonal anti-p-hp1γ (ser83)
    Rabbit Polyclonal Anti P Hp1γ (Ser83), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+hp1%CE%B3+ser83/pmc10951359-222-43-48?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal anti-p-hp1γ (ser83) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    p hp1γ ser83  (Cell Signaling Technology Inc)
    92
    Cell Signaling Technology Inc p hp1γ ser83
    (A) Representative images of <t>p-HP1γ.</t> Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.
    P Hp1γ Ser83, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+hp1%CE%B3+ser83/pmc07190998-519-48-49?v=Cell+Signaling+Technology+Inc
    Average 92 stars, based on 1 article reviews
    p hp1γ ser83 - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Representative images of p-HP1γ. Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.

    Journal: The Journal of Clinical Investigation

    Article Title: CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

    doi: 10.1172/JCI131133

    Figure Lengend Snippet: (A) Representative images of p-HP1γ. Senescence associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 in anterior prostate glands from the indicated genotypes. (C) qRT-PCR analysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble (si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.

    Article Snippet: For IHC the following antibodies were used: Ki-67 (Thermo Fisher Scientific, clone SP6, catalog RM-9106-R7; rabbit polyclonal; unmasked water bath 98°C, pH 6, 20 minutes; Lab Vision dilution ready to use); CDCP1 (Cell Signaling Technology, catalog 4115, rabbit polyclonal; unmasked water bath 98°C, pH 6, 20 minutes; 1:50); p-HP1γ-Ser83 (Cell Signaling Technology, catalog 2600, unmasked water bath 98°C, pH 6, 20 minutes; 1:50); Cyclin D1 (Cell Signaling Technology, catalog 2978S); AR (N-20) (Santa Cruz Biotechnology, catalog SC-816, rabbit polyclonal; unmasked water bath 98°C, pH 6, 20 minutes; 1:300); wide spectrum cytokeratin (pankeratin) (DAKO, catalog Z0622; rabbit polyclonal; unmasked water bath 98°C, pH 9, 20 minutes; 1:2000).

    Techniques: Staining, Western Blot, Quantitative RT-PCR, Expressing, Transfection, Binding Assay, Negative Control